Acorda acquires NeurogesX's pain patch and liquid for up to $12M

04/18/2013 | American City Business Journals

NeurogesX sold its Qutenza pain patch and an investigational liquid formulation called NGX-1998 to Acorda Therapeutics. NeurogesX will receive $7 million upfront, an additional $2 million if NGX-1998 wins FDA approval plus $3 million contingent on the drug's first-year sales hitting $100 million. The deal does not cover Europe, the Middle East or Africa, where Astellas Pharma holds marketing rights.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL